Mineralys Therapeutics, Inc. (NASDAQ:MLYS – Get Free Report) Director Ra Capital Management, L.P. acquired 1,296,296 shares of the stock in a transaction on Thursday, March 13th. The stock was bought at an average cost of $13.50 per share, with a total value of $17,499,996.00. Following the completion of the transaction, the director now owns 4,280,051 shares in the company, valued at $57,780,688.50. This trade represents a 43.45 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Mineralys Therapeutics Stock Down 0.2 %
MLYS opened at $14.22 on Tuesday. The company has a market cap of $708.67 million, a price-to-earnings ratio of -3.91 and a beta of 1.50. Mineralys Therapeutics, Inc. has a 52-week low of $8.24 and a 52-week high of $18.29. The firm’s fifty day simple moving average is $10.45 and its two-hundred day simple moving average is $11.94.
Mineralys Therapeutics (NASDAQ:MLYS – Get Free Report) last issued its earnings results on Wednesday, February 12th. The company reported ($0.98) EPS for the quarter, beating analysts’ consensus estimates of ($1.00) by $0.02. On average, research analysts forecast that Mineralys Therapeutics, Inc. will post -4.23 EPS for the current year.
Institutional Investors Weigh In On Mineralys Therapeutics
Wall Street Analysts Forecast Growth
Several equities research analysts have recently weighed in on MLYS shares. The Goldman Sachs Group lowered their price target on shares of Mineralys Therapeutics from $28.00 to $24.00 and set a “buy” rating for the company in a research report on Thursday, February 13th. Guggenheim restated a “buy” rating on shares of Mineralys Therapeutics in a research note on Monday, February 24th. Finally, HC Wainwright restated a “buy” rating and set a $30.00 price target on shares of Mineralys Therapeutics in a research note on Monday, March 10th.
Check Out Our Latest Research Report on Mineralys Therapeutics
About Mineralys Therapeutics
Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.
See Also
- Five stocks we like better than Mineralys Therapeutics
- What is a buyback in stocks? A comprehensive guide for investors
- Can TikTok Stock Picks Really Make You Rich?
- What Are Treasury Bonds?
- The “Quality” Rotation: Back to Basics Investing
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Occidental Petroleum: 4 Reasons to Love These Prices
Receive News & Ratings for Mineralys Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mineralys Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.